Arbaclofen in fragile X syndrome: results of phase 3 trials

Autor: Maryann Cherubini, Karen Walton-Bowen, Randi J Hagerman, Peter Zarevics, Walter E. Kaufmann, Elizabeth Berry-Kravis, Jeannie Visootsak, Dejan B. Budimirovic, Mark F. Bear, Paul Wang, Randall L. Carpenter

Publikováno v: Journal of neurodevelopmental disorders, vol 9, iss 1
Journal of Neurodevelopmental Disorders
BioMedCentral
Journal of Neurodevelopmental Disorders, Vol 9, Iss 1, Pp 1-18 (2017)

Background: Arbaclofen improved multiple abnormal phenotypes in animal models of fragile X syndrome (FXS) and showed promising results in a phase 2 clinical study. The objective of the study is to determine safety and efficacy of arbaclofen for socia

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::133f24559988a642d80bb3814191c8cf
https://escholarship.org/uc/item/1w01b91f

Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: a 3-month randomized controlled study

Autor: Miganush Stepanians, Thomas B. Casale, Louise Dube, William E. Berger, Harold S. Nelson, Jonathon Corren, Karen Walton-Bowen, Nicole LaVallee, James P. Kemp

Publikováno v: Annals of Allergy, Asthma & Immunology. 99:178-184

Background A controlled-release (CR) formulation of zileuton was developed to simplify administration from 600 mg 4 times daily (Zyflo) to 1,200 mg twice daily. Objective To evaluate the efficacy of zileuton CR, two 600-mg tablets twice daily, compar

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70258842ee253d0f4b8769df5b5a4369
https://doi.org/10.1016/s1081-1206(10)60642-4

Comparable Efficacy of Administration with Face Mask or Mouthpiece of Nebulized Budesonide Inhalation Suspension for Infants and Young Children with Persistent Asthma

Autor: Sherahe Fitzpatrick, Jeffrey Leflein, Mario Cruz-Rivera, Karen Walton-Bowen, Michael Mellon, Joseph A. Smith

Publikováno v: American Journal of Respiratory and Critical Care Medicine. 162:593-598

A randomized, double-blind, placebo-controlled, parallel-group study including 481 children at 37 centers in the United States demonstrated the efficacy and safety of budesonide inhalation suspension in doses of 0.25 mg once daily, 0.25 mg twice dail

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::628fb3b60dd829443f4239364e2c85b0
https://doi.org/10.1164/ajrccm.162.2.9909030

Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children

Autor: James P. Kemp, Mario Cruz-Rivera, Joseph A. Smith, David P. Skoner, Karen Walton-Bowen, Stanley J. Szefler

Publikováno v: Annals of Allergy, Asthma & Immunology. 83:231-239

Background Inhaled glucocorticosteroids (GCS) are the most effective long-term controller medications for the treatment of persistent asthma. Currently, however, available delivery devices limit their use in young children. A nebulized formulation of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41f7ef8896d06455a473fdd470448360
https://doi.org/10.1016/s1081-1206(10)62646-4

Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid–dependent, persistent asthma☆☆☆★★★

Autor: Michael J. Kraemer, Mario Cruz-Rivera, Gail G. Shapiro, Karen Walton-Bowen, Joseph A. Smith, Louis M. Mendelson

Publikováno v: Journal of Allergy and Clinical Immunology. 102:789-796

Background: Inhaled glucocorticosteroids are indicated for the treatment of persistent asthma; however, many young children are unable to effectively use currently available inhalers. Objective: We sought to evaluate the efficacy and safety of 3 diff

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::af9f679f7c9c11c20abf192ed131c732
https://doi.org/10.1016/s0091-6749(98)70019-3